ALPN — Alpine Immune Sciences Share News
0.000.00%
Last trade - 00:00- $4.46bn
- $4.15bn
- $58.88m
Brief: Alpine Immune Sciences Inc - ALPN-303 Well-Tolerated In Phase 1 Healthy Volunteer Study With On-Target Effects On Key Biomarkers
Brief: Alpine Immune Sciences Announces R&D Day To Provide Clinical Updates On ALPN-303 And Davoceticept
Brief: Alpine Immune Sciences Provides Corporate Update And Reports Second Quarter 2022 Financial Results
Brief: Alpine Immune Sciences Announces Presentations At The 2022 Eular And ASCO Annual Meetings
Brief: Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold On Clinical Trial Of Davoceticept In Combination With Pembrolizumab
Alpine Immune Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Alpine Immune Sciences Reports First Quarter 2022 Results
Alpine Immune Sciences Inc expected to post a loss of 19 cents a share - Earnings Preview
Alpine Immune Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Alpine Immune Reports Q4 And Full Year 2021 Financial Results
Alpine Immune Sciences Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Cara Therapeutics, DT Midstream, Fulcrum Therapeutics
Alpine Immune drops as U.S. FDA places cancer study on partial clinical hold
Brief: Alpine Immune Sciences Reports FDA Partial Clinical Hold On Neon-2 Trial Of Davoceticept
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:00 AM
Brief: Alpine Immune Sciences And Horizon Therapeutics PLC Announce Exclusive License And Collaboration Deal
Brief: Alpine Immune Sciences And Horizon Therapeutics PLC Announce Exclusive License And Collaboration DEAL
Alpine Immune Sciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Alpine Immune Sciences Posts Q3 Loss Per Share Of $0.55